EU/3/14/1401: Orphan designation for the treatment of traumatic spinal cord injury
Riluzole
Table of contents
Overview
On 16 December 2014, orphan designation (EU/3/14/1401) was granted by the European Commission to Dr Laurent Vinay, France, for riluzole for the treatment of traumatic spinal cord injury.
Key facts
Active substance |
Riluzole
|
Intended use |
Treatment of traumatic spinal cord injury
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/14/1401
|
Date of designation |
16/12/2014
|
Sponsor |
Dr Laurent Vinay
Institut des Neurosciences de la Timone Campus Santé Timone 27 bd Jean Moulin 13385 Marseille cedex 05 France Tel. +33 4 91 32 40 51 Fax +33 4 91 32 40 56 E-mail: laurent.vinay@univ-amu.fr |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: